Key facts
- It has raised $8.2M; the latest was Later Stage VC in Jul 2025.
- Notable investors include FinTech Innovation Lab, Bulba Ventures, Leonid Lozner, Melnichek Investments, VitaDAO.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Gero
- ·The full record, as it builds
Funding rounds
No funding rounds for Gero are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gero
Operator of a preclinical-stage biotechnology company intended to create therapeutics against the root causes of age-related and other chronic diseases. The company uses AI to create disease phenotypes in real-world human data and identify diseases with shared biology, enabling medical practitioners to extend a healthy lifespan and delay age-related health issues.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2018
- Employees
- 20
- Website
- gero.ai/
- Ownership
- Privately Held (backing)
Gero doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gero shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gero in its N-PORT filings yet. We sweep new filings monthly.